Neurology - STAT

Biotech By Nicholas Florko

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

Biotech By Felice J. Freyer — Boston Globe

What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead

Health By Erika Check Hayden

The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price

Pharmalot By Ed Silverman

Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year

Health By Mario Aguilar

Akili’s therapeutic video game will be tested as a treatment for Covid ‘brain fog’

First Opinion Podcast By Patrick Skerrett

Jason Karlawish and an Alzheimer’s caregiver on dementia’s ripple effect

Pharmalot By Ed Silverman

With time running out, an ALS patient fights with Biogen over expanded access to its drug

Pharmalot By Ed Silverman

Medicare spending on neurology drugs jumped, while number of claims barely budged

Biotech By Damian Garde

Ovid sells off its lead drug to double down on neuro research

Health By Rebecca Sohn

With chronic migraines, she avoided light for 18 months — and developed a condition from centuries past

Biotech By Adam Feuerstein

Brainstorm’s cell therapy for ALS lacks convincing clinical data for FDA submission, agency concludes

In the Lab By Nicholas St. Fleur

STAT+ Conversations: A conversation on race, science, and advocacy with Black in Neuro founder Angeline Dukes

In the Lab By Theresa Gaffney

Studying brain organoids with a Neanderthal gene, scientists unlock clues to modern human evolution

Health Tech By Mario Aguilar

Apple Watch can help track Parkinson’s disease symptoms, research shows

Biotech By Adam Feuerstein and Damian Garde

FDA delays approval decision for Biogen’s Alzheimer’s treatment

Health By Theresa Gaffney

Scientists create a thermostat for blood pressure to help patients with spinal cord injuries

In the Lab By Kate Sheridan

New research underscores the link between multiple sclerosis and the gut microbiome

Health By Priyanka Runwal

New screening technique turns up genes tied to microcephaly, scientists say, and could be used for other developmental disorders

Health By Andrew Joseph

Her father developed dementia. She made a documentary — a surreal, hilarious one — about the end of his life

In the Lab By Meghana Keshavan

Experimental drug for ALS, dreamed up in a dorm room, offers patients glimmer of hope

Health By Natalya Ortolano

‘We do belong here’: The scientist behind #BlackInNeuro hopes to transform a Twitter movement into a lasting community

Pharmalot By Ed Silverman

Pharmalittle: FDA approves another Duchenne muscular dystrophy drug; European orphan drug incentives questioned

Biotech By Kate Sheridan

4 questions for neurology startups as venture investors pour millions into the field

Health By Andrew Joseph

When Covid-19 hits the brain, it can cause strokes, psychosis and a dementia-like syndrome, new survey shows

In the Lab By Natalya Ortolano

Most Read

Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder

Biogen to expand access to its ALS drug, but move may come too late for some patients

1 in 3 Covid-19 patients are diagnosed with a neuropsychiatric condition in the next six months, large study finds

When even soft noises feel like a knife to the eardrums

Covid-19 gave scientists an opening to better understand how brain disorders arise

A new crop of medical devices are trying to hack the vagus nerve to treat disease

Muhammad Ali and Parkinson’s disease: Was boxing to blame?

FDA wants more data on promising ALS drug, frustrating patients seeking faster access

All Coverage

Advocates blast the FDA for not moving as fast on ALS as on Alzheimer’s

What’s next for the new Alzheimer’s drug? Lots of thorny issues ahead

The parents hoped an existing drug might keep their kids from having seizures. Then they saw the price

Biogen’s Alzheimer’s drug may only be cost effective at $2,500 a year

Akili’s therapeutic video game will be tested as a treatment for Covid ‘brain fog’

Jason Karlawish and an Alzheimer’s caregiver on dementia’s ripple effect

With time running out, an ALS patient fights with Biogen over expanded access to its drug

Medicare spending on neurology drugs jumped, while number of claims barely budged

Ovid sells off its lead drug to double down on neuro research

With chronic migraines, she avoided light for 18 months — and developed a condition from centuries past

Brainstorm’s cell therapy for ALS lacks convincing clinical data for FDA submission, agency concludes

STAT+ Conversations: A conversation on race, science, and advocacy with Black in Neuro founder Angeline Dukes

Studying brain organoids with a Neanderthal gene, scientists unlock clues to modern human evolution

Apple Watch can help track Parkinson’s disease symptoms, research shows

FDA delays approval decision for Biogen’s Alzheimer’s treatment

Scientists create a thermostat for blood pressure to help patients with spinal cord injuries

New research underscores the link between multiple sclerosis and the gut microbiome

New screening technique turns up genes tied to microcephaly, scientists say, and could be used for other developmental disorders

Her father developed dementia. She made a documentary — a surreal, hilarious one — about the end of his life

Experimental drug for ALS, dreamed up in a dorm room, offers patients glimmer of hope

‘We do belong here’: The scientist behind #BlackInNeuro hopes to transform a Twitter movement into a lasting community

Pharmalittle: FDA approves another Duchenne muscular dystrophy drug; European orphan drug incentives questioned

4 questions for neurology startups as venture investors pour millions into the field

When Covid-19 hits the brain, it can cause strokes, psychosis and a dementia-like syndrome, new survey shows

A preliminary new method could restore the brain cells Parkinson’s disease patients lost